# FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

> **NCT04167007** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 400 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT04167007
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-20
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167007, "FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04167007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*